Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2025-03-12 Earnings Release
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Change in Sales or Profit/Loss Structure' (매출액 또는 손익구조 30% 이상 변동) disclosure. This type of filing is a standard regulatory announcement in the Korean market (DART system) used to update financial figures following an audit or internal review. It is not a full annual report (10-K) or an earnings release (ER), but rather a specific regulatory filing update regarding financial structure changes. Therefore, it falls under the 'Regulatory Filings' category. FY 2024
2025-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by L&C Bio. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and dividend approval) for the upcoming Annual General Meeting. In the context of regulatory filings, documents that provide notice of a meeting and solicit shareholder votes/information are classified as Proxy Solicitation & Information Statements (PSI).
2025-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for L&C Bio. It contains the meeting date, location, agenda items (financial statements, dividend approval, board appointments), and details regarding electronic voting and proxy solicitation. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and request their participation/votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2025-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, proxy voting procedures, and financial statements for the fiscal year 2024. While it contains financial data, the primary purpose of this specific document is to solicit proxies from shareholders for the AGM. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2025-03-12 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service of South Korea. It details the finalization of an asset acquisition (자산양수도) by L&C Bio, confirming the payment of funds and the completion of the transaction. Since this document relates to a corporate acquisition/merger activity, it falls under the M&A Activity category.
2025-03-06 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's leadership (CEO/Representative Director). It explicitly lists the 'before' and 'after' status of the Representative Director, the reason for the change, and the board resolution date. This falls directly under the definition of Board/Management Information (MANG).
2025-03-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.